Cargando…

A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure

While traditional cytotoxic agents play a limited role in advanced dermatofibrosarcoma protuberans (DFSP), the treatment of sunitinib for patients with advanced DFSP after imatinib failure is not well defined. The objective of this case report was to analyze the relationship between molecular mechan...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Wei, Que, Yi, Peng, Ruiqing, Ding, Ya, Zhao, Jingjing, Wen, Xizhi, Weng, Desheng, Zhang, Xiaoshi, Guan, Yuanxiang, Zhang, Xing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937482/
https://www.ncbi.nlm.nih.gov/pubmed/29760553
http://dx.doi.org/10.2147/OTT.S150235
_version_ 1783320632978571264
author Xiao, Wei
Que, Yi
Peng, Ruiqing
Ding, Ya
Zhao, Jingjing
Wen, Xizhi
Weng, Desheng
Zhang, Xiaoshi
Guan, Yuanxiang
Zhang, Xing
author_facet Xiao, Wei
Que, Yi
Peng, Ruiqing
Ding, Ya
Zhao, Jingjing
Wen, Xizhi
Weng, Desheng
Zhang, Xiaoshi
Guan, Yuanxiang
Zhang, Xing
author_sort Xiao, Wei
collection PubMed
description While traditional cytotoxic agents play a limited role in advanced dermatofibrosarcoma protuberans (DFSP), the treatment of sunitinib for patients with advanced DFSP after imatinib failure is not well defined. The objective of this case report was to analyze the relationship between molecular mechanisms and clinical outcomes of sunitinib treatment in patients with advanced DFSP after imatinib failure. In this case report, a 37-year-old man suffered from advanced DFSP progression after surgical operation, microwave ablation, and chemotherapy. The immunohistochemistry in this patient revealed abundant expression of platelet-derived growth factor receptor-beta on tumor cells, which is one of the drug targets of sunitinib. The nucleotide sequence analysis revealed COL1A1-PDGFB fusion transcripts in this patient. Thus, we treated the patient with sunitinib, a multi-targeted tyrosine kinase inhibitor, after imatinib failure. After treatment with sunitinib, the patient exhibited a partial response and 9 months’ progression-free survival without significant adverse drug effects. In our case, the patient with advanced DFSP experienced a favorable outcome in 9-months’ progression-free survival and a significant improvement of quality of life without serious side effects after sunitinib treatment. Therefore, sunitinib could serve as another treatment option for patients with advanced DFSP.
format Online
Article
Text
id pubmed-5937482
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-59374822018-05-14 A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure Xiao, Wei Que, Yi Peng, Ruiqing Ding, Ya Zhao, Jingjing Wen, Xizhi Weng, Desheng Zhang, Xiaoshi Guan, Yuanxiang Zhang, Xing Onco Targets Ther Case Report While traditional cytotoxic agents play a limited role in advanced dermatofibrosarcoma protuberans (DFSP), the treatment of sunitinib for patients with advanced DFSP after imatinib failure is not well defined. The objective of this case report was to analyze the relationship between molecular mechanisms and clinical outcomes of sunitinib treatment in patients with advanced DFSP after imatinib failure. In this case report, a 37-year-old man suffered from advanced DFSP progression after surgical operation, microwave ablation, and chemotherapy. The immunohistochemistry in this patient revealed abundant expression of platelet-derived growth factor receptor-beta on tumor cells, which is one of the drug targets of sunitinib. The nucleotide sequence analysis revealed COL1A1-PDGFB fusion transcripts in this patient. Thus, we treated the patient with sunitinib, a multi-targeted tyrosine kinase inhibitor, after imatinib failure. After treatment with sunitinib, the patient exhibited a partial response and 9 months’ progression-free survival without significant adverse drug effects. In our case, the patient with advanced DFSP experienced a favorable outcome in 9-months’ progression-free survival and a significant improvement of quality of life without serious side effects after sunitinib treatment. Therefore, sunitinib could serve as another treatment option for patients with advanced DFSP. Dove Medical Press 2018-05-01 /pmc/articles/PMC5937482/ /pubmed/29760553 http://dx.doi.org/10.2147/OTT.S150235 Text en © 2018 Xiao et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Case Report
Xiao, Wei
Que, Yi
Peng, Ruiqing
Ding, Ya
Zhao, Jingjing
Wen, Xizhi
Weng, Desheng
Zhang, Xiaoshi
Guan, Yuanxiang
Zhang, Xing
A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure
title A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure
title_full A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure
title_fullStr A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure
title_full_unstemmed A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure
title_short A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure
title_sort favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937482/
https://www.ncbi.nlm.nih.gov/pubmed/29760553
http://dx.doi.org/10.2147/OTT.S150235
work_keys_str_mv AT xiaowei afavorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure
AT queyi afavorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure
AT pengruiqing afavorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure
AT dingya afavorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure
AT zhaojingjing afavorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure
AT wenxizhi afavorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure
AT wengdesheng afavorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure
AT zhangxiaoshi afavorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure
AT guanyuanxiang afavorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure
AT zhangxing afavorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure
AT xiaowei favorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure
AT queyi favorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure
AT pengruiqing favorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure
AT dingya favorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure
AT zhaojingjing favorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure
AT wenxizhi favorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure
AT wengdesheng favorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure
AT zhangxiaoshi favorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure
AT guanyuanxiang favorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure
AT zhangxing favorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure